New drug duo shows promise for tough ovarian cancers
NCT ID NCT03462342
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times
Summary
This study tested a combination of two drugs, AZD6738 and olaparib, in 123 women whose ovarian cancer had returned. The goal was to see if the combo was safe and how well it shrank tumors or slowed cancer growth. Participants had either platinum-sensitive or platinum-resistant cancer, and the trial measured side effects and response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH-GRADE SEROUS CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
Johns Hopkins University School of Medicine
Baltimore, Maryland, 21287, United States
Conditions
Explore the condition pages connected to this study.